FDI World Dental Federation and Smile Train: Children with clefts are at high risk for tooth decay, gum disease and other serious oral health concerns
mehr
Storys zum Thema Medikament
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Tennis Champion Caroline Wozniacki and UCB Launch Advantage Hers Campaign for Women with Chronic Inflammatory Diseases
Brussels, Belgium (ots/PRNewswire) - - Grand Slam winner Caroline Wozniacki is the highest-ranking female athlete known to have been diagnosed with rheumatoid arthritis whilst still playing professional tennis - Advantage Hers will equip and empower women around the world living with chronic inflammatory diseases, ...
mehrReal Time Medical Launches AI-Enabled App to Deliver Peer-Reviewed Data and Advice to Manage the COVID-19 Pandemic
Toronto (ots/PRNewswire) - Drawing only on trusted medical sources and overlaid with the latest federal health guidelines, COVID AIKnowledgeEnableTM arms healthcare professionals and health conscious individuals with the information they need to make better decisions Real Time Medical ("RTM" or "the Company"), a ...
mehrMSD (Merck Sharp & Dohme AG) Switzerland appoints Ans Heirman, Ph.D. as the new Managing Director of MSD Switzerland, effective September 1st, 2020
Ein DokumentmehrNew 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and elderly AF patients on LIXIANA (edoxaban) during routine clinical care
Munich (ots/PRNewswire) - - Newly presented data provide reassurance around edoxaban use in vulnerable populations of frail, elderly and renally impaired patients - Clinician's perception of frailty found to potentially be a better marker of clinical outcomes than age - The global ETNA-AF programme, which includes ...
mehrDEBIOPHARM'S NEW GENERATION RADIONUCLIDE THERAPY ADVANCES INTO CLINICAL RESEARCH IN THE FIGHT AGAINST LUNG CANCER
Lausanne (ots) - First patient dosed in the phase I small cell lung cancer (SCLC) trial with Debio 1124, a molecular-targeted radiotherapy Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced the first patient dosed in the multicenter, single-arm, open-label Phase 1 study ...
mehrETNA-AF-Europe Registry Data on LIXIANA®(edoxaban) Published in a Leading Cardiology Journal Highlights Important Clinical Considerations for Treating Ageing Patients with Atrial Fibrillation
Munich (ots/PRNewswire) - - Publication highlights Europe-specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients[1] - Findings are ...
mehrNorgine B.V. Completes Important Regulatory Milestone For Angusta® (Misoprostol) In Europe For Oral Induction Of Labour
Amsterdam (ots/PRNewswire) - - Norgine will now seek to extend ANGUSTA®'s licence to a number of European countries - ANGUSTA®'s licence extension for these countries will be subject to national approvals Norgine B.V. (Norgine) today announced the successful completion of the Repeat Use Procedure (RUP) for ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
28 new coronavirus research projects funded under NRP "COVID-19"
Bern (ots) - New research has been launched to better control COVID-19. 18.6 million francs have been invested in projects that will investigate innovative solutions and develop public health recommendations. Mandated by the Federal Council, the SNSF launched the National Research Programme "COVID-19" (NRP 78) on 30 April 2020 to advance our understanding of the ...
mehrNorgine; AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals and Norgine B.V. Enter Into Exclusive Licensing Agreement to Commercialize Ciraparantag in Europe, Australia and New Zealand
Waltham, Mass. and Amsterdam (ots/PRNewswire) - Agreement provides AMAG with $30 million upfront payment and eligibility to receive up to $260 million in development and commercial milestones in addition to sales royalties Collaboration further advances the development of ciraparantag AMAG Pharmaceuticals, Inc. ...
mehrVersameb raises CHF 6 million and strengthens team to advance its VERSagile technology platform towards clinical trials
Basel, Switzerland (ots) - Versameb AG, a biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, announced today the closing of a CHF 6 million seed financing round. Versameb further strengthens its team by the appointment of Dr. Klaas P. Zuideveld as Chief Development Officer effective ...
mehrRates of Bleeding and Venous Thromboembolism (VTE) Events Reported After 12 Months of Edoxaban Treatment Considered Low by Real-world ETNA-VTE Study Investigators
Munich (ots/PRNewswire) - - Daiichi Sankyo presented five abstracts from the Global and European ETNA-VTE registry studies at ISTH 2020 Virtual Congress - Data are from 4,595 VTE patients (mean age 64) from 583 sites across Europe, Japan and other East and South-east Asian countries - Real-world study adds to the ...
mehrCarag Receives U.S. FDA IDE Approval to Conduct Clinical Study of First Transcatheter Septal Occluder With Bioresorbable, Metal-free Framework
Baar, Switzerland (ots/PRNewswire) - The U.S. trial for CE-marked CBSO is designed to enroll up to 250 patients in a staged study approach CARAG AG, a privately-held Swiss medical device development company, today announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) ...
mehrMental Health Care Company COMPASS Pathways Strengthens Leadership Team With Appointment of Trevor Mill as Chief Development Officer
London (ots/PRNewswire) - - Piers Morgan appointed earlier in the year as Chief Financial Officer and Gary Gilmour as Director of Preclinical Research COMPASS Pathways, a mental health care company, announced today that it has made a number of new appointments to its leadership team. Trevor Mill joins the company as ...
mehrInvestigational, Once-weekly Insulin Icodec Showed Comparable Efficacy and Safety to Once-daily Insulin Glargine U100 in Phase 2 Trial
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only, excl US For journalistic assessment and preparation before publication. Today, Novo Nordisk announced results from a phase 2 clinical trial of investigational insulin icodec, a once-weekly basal insulin analogue. In the ...
mehrSwitching to Ozempic® from another GLP-1 RA significantly reduced blood sugar and weight in people with type 2 diabetes in routine clinical practice
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only, excl US. For journalistic assessment and preparation before publication. - A separate real-world study showed that people with type 2 diabetes on two oral antidiabetic drugs who intensified with a glucagon-like peptide-1 ...
mehrInternational Atherosclerosis Society
International Atherosclerosis Society Issues Call to Action to Improve Lipid Management Based on Survey Results to Address Patients' Residual Risk
Milan (ots/PRNewswire) - Article and slides can be found at https://www.athero.org/activities/survey or contact Karen Foy (karen.foy@athero.org) A new survey by the International Atherosclerosis Society (IAS) provided a 'snapshot' of the gaps in knowledge among clinicians that limit best practice. This web-based ...
mehrDebiopharm's Novel Microbiome Remodeling Program Licensed to Takeda for the Treatment of Gastrointestinal Disorders
Lausanne, Switzerland (ots) - Takeda will pursue the development of a novel preclinical narrow spectrum microbiome remodeling program, to treat diseases related to dysbiosis of the human gut microbiome Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today an exclusive license agreement ...
mehrDebiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prostate Cancer
LAUSANNE, SWITZERLAND & WAYNE, PENNSYLVANIA (ots) - Debiopharm, a Swiss-based, biopharmaceutical company, and Verity Pharmaceuticals Inc., a US based specialty pharmaceutical company focused on therapeutic solutions for genitourinary (GU) diseases, today announced having entered into an exclusive agreement that ...
mehrZentiva Expands Production Capacity by Completing Acquisition of Ankleshwar Manufacturing Site
Prague (ots/PRNewswire) - Zentiva Group announces the completion of its acquisition of a manufacturing site in Ankleshwar, India, from Sanofi. The finalization of the deal increases the number of wholly-owned Zentiva production sites worldwide and will enable Zentiva to serve more people who are in daily need of our high quality, affordable medicines. "We are delighted ...
mehrChina Matters and Tianjin Haihe Media Group Released Co-produced Documentary "A Man on a Rescue Mission against COVID-19"
Tianjin, China (ots/PRNewswire) - At the age of 72, Zhang Boli, a medical professional from Tianjin, was saving lives at the forefront of the COVID-19 response in Wuhan while being saved by others. Doctor Zhang was convinced that traditional Chinese medicine (TCM) could be helpful alongside Western medicine for ...
mehrAcquisition of Debiopharm's investment portfolio company Kaiku Health broadens patient access to digital oncology intervention
Lausanne, Switzerland (ots) - - Debiopharm announces successful exit deal for Kaiku Health, a Finnish start-up specializing in digital solutions for improved patient outcomes and experience - Kaiku's acquisition by the Swedish company Elekta allows thousands of cancer treatment centers to gain access to the ...
mehrBreakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020
Darmstadt, Germany (ots/PRNewswire) - - Results from two studies of BAVENCIO® to be featured in ASCO press briefing - Primary efficacy, biomarker and HRQoL analyses for tepotinib?, the first MET inhibitor to have received a regulatory approval for NSCLC with MET gene alterations - Two-year follow-up for first-in-class bifunctional immunotherapy bintrafusp alfa? ...
mehrDpt of Precision Medicine, Maastricht University
The Department of Precision Medicine of Maastricht University Receives 920KEUR from the European Commission to Further Develop Their Work on Artificial Intelligence Tools for COVID-19 Patients
Maastricht, Netherlands (ots/PRNewswire) - The D (http://dnamito.com/) epartment of Precision Medicine (http://dnamito.com/) at (http://dnamito.com/) Maastricht University (http://dnamito.com/) (The Netherlands) announced today the release of their AI tool for COVID-19 patient triage, the same week that they ...
mehrMental Health Care Company COMPASS Pathways Concludes Successful Series B Investment Round
London (ots/PRNewswire) - $80m Raised Will Further the Development of Psilocybin Therapy COMPASS Pathways, a mental health care company, announced today that it has completed a successful $80m Series B investment round. This funding will expand upon COMPASS's lead programme in psilocybin therapy for treatment-resistant depression, supporting research into additional ...
mehrSOPHiA GENETICS Expands Its Executive Team, Naming Lara Hashimoto Chief Business Officer
Lausanne, Switzerland and Boston (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Lara Hashimoto has joined its Executive Team as Chief Business Officer, effective April 1st. She will be responsible for Marketing, Product Management and Business Development. Lara Hashimoto joined the healthcare industry 20 years ago holding ...
mehrZentiva Extends Commercial Footprint By Completing Acquisition of CEE Business From Alvogen
Prague (ots/PRNewswire) - Zentiva Group a.s. confirms the closing of its previously declared acquisition of Alvogen's Central and Eastern European (CEE) business. The deal adds to Zentiva's continuing organic growth, reinforcing Zentiva's commercial footprint in Poland, Romania and Bulgaria, and expanding its ...
mehrSaxenda® Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda® (liraglutide 3.0 mg) in adolescents (aged ...
mehrNorgine B.V. Acquires Azanta A/S, Strengthening Its Position as a Leading European Specialist Pharmaceutical Company
Amsterdam (ots/PRNewswire) - Norgine B.V. ("Norgine") announces the acquisition of Azanta A/S, a specialty biopharmaceutical company operating within women's healthcare, addiction medicine and oncology. Azanta becomes a wholly-owned subsidiary of Norgine. To view the Multimedia News Release, please click: ...
mehrCarag First-ever Septal Occluder With Bioresorbable, Metal-free Framework Available to Patients Through New European Registry
Baar, Switzerland and Berlin (ots/PRNewswire) - First 3-year-old patient successfully implanted and discharged from hospital in Berlin CARAG AG, a Swiss privately held medical device development company, announced today the successful implantation of the first-ever transcatheter septal occluder with bioresorbable, ...
mehr
Vorherige567891011121314Nächste